- Home
- RENB
as 11-21-2024 4:00pm EST
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | SUITE 906 LOS ANGELES |
| Market Cap: | 101.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 298.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $5.25 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Renovaro Biosciences Inc. News
RENB Breaking Stock News: Dive into RENB Ticker-Specific Updates for Smart Investing
GlobeNewswire
18 days ago
Renovaro Issues Shareholder Letter and Provides Corporate Update
GlobeNewswire
a month ago
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
GlobeNewswire
a month ago
Renovaro Announces Strategic Restructuring and Leadership Transition
GlobeNewswire
2 months ago
PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics
GlobeNewswire
2 months ago
Independent Expert Assessment Validates RenovaroCube’s Potential as a Groundbreaking AI Platform Starting with Early Cancer Detection
GlobeNewswire
2 months ago
RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
GlobeNewswire
2 months ago
RenovaroCube Announces Strategic Offering of Up to 20% Ownership
The Wall Street Journal
4 months ago
The Junk in Your Index Fund Is Costing You Big-Time
Compare RENB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RENB Renovaro Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.